Aigen Investment Management, LP Arvinas, Inc. Transaction History

Aigen Investment Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$24.46 - $40.4 $292,761 - $483,547	11,969 New	11,969 $318,000
Q4 2021 Feb 11, 2022	SELL	$65.85 - $96.21 $250,559 - $366,079	-3,805 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $278,526 - $410,445	3,805 New	3,805 $313,000
Q1 2021 May 11, 2021	SELL	$58.19 - $91.37 $365,724 - $574,260	-6,285 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$20.19 - $84.93 $869,441 - $3.66 Million	-43,063 Reduced 87.26%	6,285 $534,000
Q3 2020 Nov 06, 2020	BUY	$22.99 - $36.34 $248,039 - $392,072	10,789 Added 27.98%	49,348 $1.17 Million
Q2 2020 Aug 10, 2020	BUY	$29.88 - $56.74 $939,367 - $1.78 Million	31,438 Added 441.48%	38,559 $1.29 Million
Q1 2020 May 08, 2020	BUY	$33.0 - $54.5 $234,993 - $388,094	7,121 New	7,121 $287,000

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $945M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.